Flatrock Wealth Partners’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$321K Buy
6,706
+259
+4% +$11.1K 0.13% 111
2026
Q1
$245K Buy
6,447
+327
+5% +$15.5K 0.11% 125
2025
Q4
$311K Buy
+6,120
New +$313K 0.15% 99

Other funds holding NVO

Flatrock Wealth Partners's NVO Position: Q2 2026 in Review

Flatrock Wealth Partners increased its Novo Nordisk (NVO) stake by 4% in Q2 2026, buying an estimated $11.1K and bringing the position to 6,706 shares worth $321K. The position accounts for 0.13% of the portfolio, ranked #111.

Flatrock Wealth Partners first reported a position in NVO in Q4 2025 and has held it in 3 quarters since. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Flatrock Wealth Partners held 6,706 shares of Novo Nordisk worth $321K as of Q2 2026.
  • Flatrock Wealth Partners bought 259 Novo Nordisk shares in Q2 2026, an estimated $11.1K.
  • Novo Nordisk made up 0.13% of Flatrock Wealth Partners's portfolio in Q2 2026, its #111 holding.
  • Flatrock Wealth Partners first reported a position in Novo Nordisk in Q4 2025 and has held it in 3 quarters since.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Flatrock Wealth Partners's 13F filing for Q2 2026, filed 14 Aug 2026.